BICYCLE THERAPEUTICS PLC's ticker is BCYC and the CUSIP is 088786108. A total of 99 filers reported holding BICYCLE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is 2.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,350,911 | -27.0% | 266,347 | -7.2% | 0.00% | -100.0% |
| Q2 2023 | $7,327,991 | -40.0% | 287,147 | -50.0% | 0.00% | 0.0% |
| Q1 2023 | $12,215,234 | +9.3% | 574,294 | +52.1% | 0.00% | 0.0% |
| Q4 2022 | $11,178,351 | -27.7% | 377,647 | -43.2% | 0.00% | -50.0% |
| Q3 2022 | $15,463,000 | +30.1% | 664,806 | -6.1% | 0.00% | +100.0% |
| Q2 2022 | $11,882,000 | -66.3% | 708,080 | -11.9% | 0.00% | -66.7% |
| Q1 2022 | $35,268,000 | -60.3% | 803,748 | -45.0% | 0.00% | -57.1% |
| Q4 2021 | $88,924,000 | +363.2% | 1,460,882 | +216.5% | 0.01% | +250.0% |
| Q3 2021 | $19,199,000 | +199.1% | 461,629 | +118.3% | 0.00% | +100.0% |
| Q2 2021 | $6,419,000 | +1.6% | 211,444 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $6,316,000 | +66.4% | 211,444 | 0.0% | 0.00% | – |
| Q4 2020 | $3,795,000 | -5.8% | 211,444 | 0.0% | 0.00% | – |
| Q3 2020 | $4,028,000 | +22.9% | 211,444 | 0.0% | 0.00% | – |
| Q2 2020 | $3,277,000 | – | 211,444 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 917,218 | $40,248,000 | 48.61% |
| GREAT POINT PARTNERS LLC | 550,592 | $24,160,000 | 5.84% |
| Logos Global Management LP | 950,000 | $41,686,000 | 5.40% |
| Deep Track Capital, LP | 1,855,993 | $81,441,000 | 5.22% |
| First Light Asset Management, LLC | 890,174 | $39,061,000 | 3.44% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 1,154,126 | $50,643,000 | 3.00% |
| Ikarian Capital, LLC | 478,784 | $21,009,000 | 2.76% |
| Opaleye Management Inc. | 175,000 | $7,679,000 | 2.38% |
| Frazier Life Sciences Management, L.P. | 603,521 | $26,483,000 | 2.26% |
| Altium Capital Management LP | 120,000 | $5,266,000 | 1.76% |